Combined with systemic checkpoint blockade therapy (antiprogrammed cell death–ligand 1, anti‐PD‐L1), 131I‐VNP combination therapy can further inhibit the growth of colon cancer in situ and prevent tumor recurrence and metastasis.[166]. This evidence concerns the gene CD274 and neoplasm.